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Abstract: A number of 1,2-benzothiazines have been synthesized in a three-step process.
Nine chalcones 1–9 bearing methyl, fluoro, chloro and bromo substituents were chlorosulfonated with
chlorosulfonic acid to generate the chalcone sulfonyl chlorides 10–18. These were converted to the
dibromo compounds 19–27 through reaction with bromine in glacial acetic acid. Compounds 19–27
were reacted with ammonia, methylamine, ethylamine, aniline and benzylamine to generate a library
of 45 1,2-benzothiazines 28–72. Compounds 28–72 were evaluated for their antimicrobial activity
using broth microdilution techniques against two Gram-positive bacteria (Bacillus subtilis and
Staphylococcus aureus) and two Gram-negative bacteria (Proteus vulgaris and Salmonella typhimurium).
The results demonstrated that none of the compounds showed any activity against Gram-negative
bacteria P. vulgaris and S. typhimurium; however, compounds 31, 33, 38, 43, 45, 50, 53, 55, 58, 60, 63
and 68 showed activity against Gram-positive bacteria Bacillus subtilis and Staphylococcous aureus.
The range of minimum inhibitory concentration (MIC) and minimum bactericidal concentration
(MBC) was 25–600 µg/mL, though some of the MIC and MBC concentrations were high, indicating
weak activity. Structure activity relationship studies revealed that the compounds with a hydrogen
atom or an ethyl group on the nitrogen of the thiazine ring exerted antibacterial activity against
Gram-positive bacteria. The results also showed that the compounds where the benzene ring of the
benzoyl moiety contained a methyl group or a chlorine or bromine atom in the para position showed
higher antimicrobial activity. Similar influences were identified where either a bromine or chlorine
atom was in the meta position.
Keywords: 1,2-benzothiazines; chalcones; Bacillus subtilis; Staphylococcous aureus; Proteus vulgaris;
Salmonella typhimurium
1. Introduction
The emergence of drug-resistant strains of bacteria is an increasing threat to society.
Many antibiotics that were formerly effective in curing bacterial infections are no longer efficient
because of the evolution of resistant strains. Therefore, there is an urgent need for a new class of
antibacterial agents [1]. Clinically, antibiotic resistance is one of the greatest challenges of the 21st
century. Antibiotic resistance has led to the emergence of superbugs such as methicillin-resistant
Staphylococcus aureus and extremely resistant tuberculosis bacteria which are impossible to treat with
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available medicines [2,3]. New antibacterial agents are currently being developed at a much slower
pace than our growing need for such drugs. Amongst the family of heterocyclic compounds, those
with nitrogen and sulfur atoms have been identified as having the most comprehensive spectrum of
biological activities [4]. The biological and pharmacological properties of these compounds have been
demonstrated in a number of studies [4,5].
Derivatives of benzothiazine have, depending upon the substituents present, shown biological
activities that range from antipsychotic to anti-inflammatory [6–8]. The 1,2-benzothiazines
have shown various biological activities such as anti-inflammatory [9], CNS depressant [10,11],
anti-depressants [12], anticancer [13] and antimicrobial [14]. They also act as potent calpain I
inhibitors [15] and vasodilators [16]. Previous research has shown 1,2-benzothiazines to be potent
antimicrobial agents against Gram-positive bacterial strains and fungal strains such as Aspergillus flavus,
Aspergillus niger, Fusarium oxysporum [17]. In addition 1,2-benzothiazines have been seen to show
marked activity against B. subtilis [17–20]. In recent years there has been a rapid growth in the literature
pertaining to the benzothiazine ring system; much of this literature relates to the discovery that
3-carboxamides of 2-alkyl-4-hydroxy-2H-1,2-benzothiazine-1,1-dioxides are anti-inflammatory agents,
which includes the drugs piroxicam, ampiroxicam and meloxicam (Figure 1) [21–28]. The common
route to these types of compounds is via the alkoxide rearrangement of saccharin derivatives
(Scheme 1) [29–35].
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Scheme 1. Synthesis of 1,2-benzothiazines via the alkoxide rearrangement of saccharin derivatives.
There are number of differ nt synthetic routes to 1,2-benzothiazines; however, the tarting
materials are not readily available. We recently developed a straightforward route to 1,2-benzothiazines
using readily available chalcones [36]. In light of these observations, a series of new 1,2-benzothiazines
were synthesized with the aim of obtaining potential antibacterial agents.
2. Results
2.1. Chemistry
Synthetic target compounds 28–72 were sy th sized in a three-step process outlined in
Scheme 2 in yields of 44%–96%. The chalc n s 1–9, which w re sy thesize by reacting different
acetophenones with 3,4-dimethoxybenzaldehyde following known l t rature methods [37–39], were
reacted with chlorosulfonic acid at room temperature to generate the chalcone sulfonyl chlorides 10–18.
Melting points and spectral data (IR, 1H-NMR, 13C-NMR and nanoESI-MS) were consistent with
literature data (see Supplementary Materials for 1H-NMR, 13C-NMR, HSMS of representative
Molecules 2016, 21, 861 3 of 16
compounds). The sulfonyl chlorides 10–18 were deemed pure enough without recrystallization
and reacted with bromine in glacial acetic acid at room temperature, which yielded the chalcone
dibromo sulfonyl chlorides 19–27. Subsequently, the dibromo chalcone sulfonyl chlorides 19–27
were treated with ammonia and four primary amines (methylamine, ethylamine, aniline and
benzylamine) to afford a benzothiazine library of 45 compounds 28–72. The structures of the newly
synthesized benzothiazines 28–72 were appropriately characterized by spectral data. The IR spectra
of compounds 28–72 confirmed the presence of the carbonyl signal in the region 1650–1720 cm´1
and all these compounds exhibited additional bands corresponding to the SO2 group (νmax 1340 and
1170 cm´1).
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Scheme 2. Synthetic steps for compounds 10–18, 19–27 and 1,2-benzothiazines 28–72.
Compounds 29, 34, 39, 54, 59, 64 and 69 formed when the dibromo chalcone sulfonyl chlorides
were reacted with methylamine. The 1H-NMR of these compounds showed the presence of the
methylamino group in the δ 2.2–2.8 region. The methine protons all appeared as doublet-of-doublets
in all the 1,2-benzothizaines, as expected, with the exception of compound 48 which did not show
peaks for the two methine protons. Compound 48 showed two singlets at δ 3.93 and δ 4.01 for the two
methoxy groups and three singlets in the aromatic region between δ 6.86–7.84. A broad singlet at δ
8.20 was observed for the amino proton which was exchangeable with D2O. The definitive structure
of compound 48 was confirmed by spectral and X-ray analysis with the ORTEP representation of the
molecular structure shown in Figure 2b.
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2.2. Antimicrobial Screening
The synthesized compounds 28–72 (Table 1) dissolved in DMSO were evaluated for their
antimicrobial activity against bacterial strains of Bacillus subtilis ATCC 6633, Staphylococcous aureus
ATCC 6538, Salmonella typhimurium ATCC 14028 (Salmonella enterica) and Proteus vulgaris ATCC 13315
by determining their minimum inhibitory concentrations (MICs) using a micro-broth dilution technique
and their minimum bactericidal concentrations (MBCs). Their activities were compared with those
of the known antibacterial streptomycin. There was no inhibition of growth of any of the bacteria in
the presence of DMSO up to 5% concentration; however, there was a slight decrease in absorbance
between concentrations of 5% to 8%, but after 8% there was a steep decrease in absorbance showing
inhibition of growth.
Table 1. The general structure of compounds 28–72 where R1, R2 and R3 refer to substituents attached
to the benzoyl moiety while R4 and R5 refer to the substituents attached to the thiazine ring.
Compound R1 R2 R3 R4 R5
28 H H H H Br
29 H H H CH3 NHCH3
30 H H H CH2CH3 Br
31 H H H Ph Br
32 H H H PhCH2 Br
33 CH3 H H H Br
34 CH3 H H CH3 NHCH3
35 CH3 H H CH2CH3 Br
36 CH3 H H Ph Br
37 CH3 H H PhCH2 Br
38 Cl H H H Br
39 Cl H H CH3 NHCH3
40 Cl H H CH2CH3 Br
41 Cl H H Ph Br
42 Cl H H PhCH2 Br
43 Br H H H Br
44 Br H H CH3 Br
45 Br H H CH2CH3 Br
46 Br H H Ph Br
47 Br H H PhCH2 Br
48 F H H H H
49 F H H CH3 Br
50 F H H CH2CH3 Br
51 F H H Ph Br
52 F H H PhCH2 Br
53 H Cl H H Br
54 H Cl H CH3 NHCH3
55 H Cl H CH2CH3 Br
56 H Cl H Ph Br
57 H Cl H PhCH2 Br
58 H Br H H Br
59 H Br H CH3 NHCH3
60 H Br H CH2CH3 Br
61 H Br H Ph Br
62 H Br H PhCH2 Br
63 H H Cl H Br
64 H H Cl CH3 NHCH3
65 H H Cl CH2CH3 Br
66 H H Cl Ph Br
67 H H Cl PhCH2 Br
68 H H Br H Br
69 H H Br CH3 NHCH3
70 H H Br CH2CH3 Br
71 H H Br Ph Br
72 H H Br PhCH2 Br
The MICs and MBCs of selected compounds are presented against both Gram-positive and
Gram-negative bacterial strains in Table 2. Results of the anti-bacterial activity showed that the MICs
and MBCs of compounds (31, 33, 38, 43, 45, 50, 55, 58, 60, 63 and 68) varied between the ranges
of 25–600 µg/mL for B. subtilis. The MICs range of these compounds for S. aureus varied between
100–500 µg/mL whereas only compounds 53, 58 and 60 showed a bactericidal effect in the range of
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200–400 µg/mL. None of the compounds showed any activity against the selected Gram-negative
bacteria as MIC values were higher than 600 µg/mL.
The MIC of most of the compounds that showed antimicrobial activity against bacterial species
B. subtilis and S. aureus was quite high (400–600 µg/mL) as compared to streptomycin which has
a MIC of 12.5 µg/mL for Gram-positive bacteria (Table 2), therefore showing very weak antibacterial
activity as compared to streptomycin. Only compounds 33, 38, 43 and 58 showed MIC values between
25–50 µg/mL for B. subtilis (see Supplementary Materials Figures S1–S6).
Table 2. MIC and MBC (µg/mL) of selected compounds and streptomycin against Gram-positive
bacteria B. subtilis, S. aureus and Gram-negative bacteria P. vulgaris, S. typhimurium and their Clog
p-values (For MIC and MBC values in µmol/mL see Supplementary Materials Table S1).
Compound B. subtilis S. aureus P. vulgaris S. typhimurium Clog P
MIC MBC MIC MBC MIC MBC MIC MBC
31 500 500 500 >600 >600 >600 >600 >600 4.668
33 50 50 100 >600 >600 >600 >600 >600 3.316
38 50 50 100 >600 >600 >600 >600 >600 3.596
43 25 50 100 - >600 >600 >600 >600 3.746
45 500 500 500 - >600 >600 >600 >600 4.811
50 500 600 400 >600 >600 >600 >600 >600 4.091
53 100 100 100 200 >600 >600 >600 >600 3.596
55 100 100 200 >600 >600 >600 >600 >600 4.661
58 25 50 100 200 >600 >600 >600 >600 3.746
60 600 >600 400 400 >600 >600 >600 >600 4.811
63 >600 >600 400 >600 >600 >600 >600 >600 3.336
68 >600 >600 500 >600 >600 >600 >600 >600 3.486
Streptomycin 12.5 12.5 12.5 25 6.25 6.25 100 100
3. Discussion
Prompted by the well-established antibacterial properties of benzothiazines, a series of
1,2-benzothiazine derivatives, covering different modifications of the benzothiazine scaffold, were
synthesized from readily available chalcones. The title compounds were assayed in vitro for the
evaluation of their antimicrobial activity against Gram-positive and Gram-negative bacteria.
The compounds with a hydrogen or an ethyl group on the nitrogen in the thiazine rings
showed antibacterial properties against Gram-positive bacteria. The structure–antimicrobial activity
relationship in the synthesized compounds revealed that 33, 38, 43, 53, 58, 63 and 68 inhibited the
growth of Gram-positive bacteria. These compounds all contain a hydrogen atom on the nitrogen of
the thiazine ring. This suggests that the amino group in the thiazine ring may be playing a role in
the antibacterial property of these compounds. The results, therefore, support previous work which
revealed that 4H-1,4-benzothiazines showed antibacterial activity against Gram-positive bacteria and
fungi but no significant activity against Gram-negative bacteria [37]. In addition to this, compounds
with an ethyl moiety on the nitrogen, 45, 50, 55 and 60, showed some inhibition of Gram-positive
bacteria, though at higher concentrations.
In previous work on 1,4-benzothiazines, it was noted that the presence of an extra nitrogen
and oxygen atom increases the lipophilicity of the compounds [37]. They reported that in a series
of 1,2-benzothiazine-1,1-dioxides (N-methyl analogues), the compounds with greater lipophilicity
possessed higher antibacterial activity. In the current work, compounds 29, 34, 39, 54, 59, 64 and 69
(N-methyl analogues) showed no activity, while 33, 38, 43, 53, 58, 63 and 68 showed weak antibacterial
activity. These results are in contrast with the work of Ahmed and colleagues [37]. On the other hand,
compounds 45, 50, 55 and 60 (N-ethyl analogues) showed some antibacterial activity which is in line
with previous work [37].
The reaction of methylamine with the dibromo sulfonyl chlorides 19–27 unexpectedly resulted
in the 4-methyamino derivatives 29, 34, 39, 54, 59, 64 and 69 which showed no antibacterial activity.
However, the compounds with a bromine atom on carbon-4 in the thiazine ring displayed weak
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antibacterial activity, which would suggest that a bromine atom may be playing some role. This is
supported by the fact that compound 48 did not show any antibacterial activity.
The presence of different substituents in the benzene ring of the benzoyl moiety also had an effect
on the antibacterial activity against B. subtilis. Compounds with a chlorine or bromine atom or a methyl
group in the para position showed increased antibacterial activity and a bromine atom in the meta
position gave similar results. Amongst the compounds which contain no substituents in the benzene
ring, only 31 showed very weak antibacterial activity (MIC of 500 µg/mL for B. subtilis and S. aureus)
while compounds 28–30 and 32 showed no activity. However, compounds substituted with methyl,
chloro, bromo and fluoro substituents in the meta or para position showed inhibition for B. subtilis.
The ortho-substituted compounds with the same substituents inhibited S. aureus weakly.
In summary, the study conducted in this work has designed a simple synthetic route to
1,2-benzothiazines from readily available starting materials. Some of the compounds (33, 38, 43,
45, 50, 53, 55 and 58) synthesized, based on a library of 45 structures, showed some biological activity
against Gram-positive bacteria B. subtilis and S. aureus, though the antibacterial activity was very weak
as compared to the reference streptomycin standard. Based on our results, in vitro cytotoxicity work
was not conducted for these compounds.
4. Experimental Section
4.1. General Information
All chemicals were purchased form Sigma Aldrich (St. Louis, MO, USA) and were used without
any further purification. Melting points were determined using a Gallenkamp melting point apparatus
(Thermo Fisher Scientific, Paisley, UK) and are uncorrected. The NMR spectra were recorded using
a 600 MHz spectrometer (JEOL Co Ltd., Tokyo, Japan) with tetramethylsilane as internal standard
and solvents as indicated. Chemical shifts were measured in ppm (δ) relative to TMS (0.00 ppm).
Coupling constants (J) are reported in Hertz (Hz). The following abbreviations are used to describe the
signal multiplicities: s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). Accurate mass
measurements were made at the National Mass Spectrometry Facility using Thermo Scientific LTQ
Orbitrap XL with Advion Nanomate nanoelectrospray system (Waltham, MA, USA). Infrared spectra
were recorded with a Varian spectrophotometer as KBr discs. TLC (thin layer chromatography) was
performed using silica gel plates by dissolving the compound in dichloromethane and using the
solvent system dichloromethane and diethyl ether. Clog P values were calculated using ChemBioDraw
Ultra 13.0 (CambridgeSoft, Perkin Elmer, UK).
4.2. Synthesis of Chalcones
Chalcones 1–9 were synthesized by the well-established procedure using acetophenones and
3,4-dimethoxybenzaldehyde [38].
4.3. General Procedure for the Synthesis of Chalcone Sulfonyl Chlorides 10–18
The chalcones 1–9, (10 g; 0.032 mol) were added in portions to stirred chlorosulfonic acid (37.67 g;
0.32 mol) in an ice bath. After the addition was complete the reaction mixture was left stirring at
room temperature. Progress of the reaction was monitored by thin layer chromatography (TLC).
When the reaction was complete (24 h), the mixture was poured slowly over ice to remove the excess
chlorosulfonic acid. The sulfonyl chloride was filtered by suction filtration and washed with cold water
acetonitrile mixture. The resulting precipitate was considered pure enough to be used in subsequent
reactions by TLC analysis.
4.4. General Procedure for the Synthesis of Dibromo Chalcone Sulfonyl Chlorides 19–27
The crude chalcone sulfonyl chloride 10–18 (10 g; 0.032 mol) was added to glacial acetic acid
(125 mL) with stirring. The resulting mixture was stirred at room temperature and to the stirred
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mixture was added bromine (20.48 g; 0.13 mol) dissolved in 50 mL glacial acetic acid. The mixture was
stirred until a precipitate was formed which was filtered and washed with cold glacial acetic acid.
4.5. General Procedure for the Synthesis of Benzothiazines 28–72
To a stirred solution, at room temperature compounds 19–27, (1 g) in ethanol (25 mL) were added
drop-wise to a primary amine (3 mol equivalent). The mixture was warmed on a water bath for
10–20 min making sure that the solvent does not evaporate. The mixture was then stirred at room
temperature for a further half hour and then ice was added until a precipitate appeared. The resulting
solid was filtered and allowed to dry overnight and recrystallized from the appropriate solvent.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(phenyl)methanone (28).
Recrystallization solvent: ethanol; yield 68.7%; mp 203–204 ˝C; IR (KBr, ν cm´1) 1688.9 (C=O), 1598.8
(C-C, aromatic), 1329.6, 1146.2 (SO2). 1H-NMR (CDCl3): δ 3.87 (d, 1H), 3.93 (s, 3H, OCH3), 3.95 (s, 3H,
OCH3), 4.51(d, 1H), 7.00–8.10 (m, 7H, Ar-H). 13C-NMR (CDCl3): δ 30.00, 46.00, 54.25, 56.51, 103.00,
107.00, 112.50, 117.00, 120.00, 128.50, 134.00, 138.00, 149.00, 151.50, 192.10. HR-MS (nES) m/z calcd
[M + H]+ 346.0744: observed 346.0741.
(6,7-Dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(phenyl)
methanone (29). Recrystallization solvent: ethanol; yield 79.5%; mp 190–192 ˝C. IR (KBr, ν cm´1) 1598.1
(C=O), 1545.0 (C-C, aromatic), 1383.6, 1157.1 (SO2). 1H-NMR (CDCl3): δ 2.61 (d, 3H, CH3), 2.80 (s, 3H,
CH3), 3.93 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 5.63(d, 1H), 6.80 (s, 1H), 7.24–7.79 (m, 7H, Ar-H), 11.4
(broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR (CDCl3): δ 9.00, 11.00, 30.10, 30.40, 32.10,
32.20, 55.10, 54.20, 101.00, 112.00, 113.00, 126.00, 126.40, 126.81, 128.37, 128.40, 132.00, 160.00, 192.00.
HR-MS (nES) m/z calcd [M + H]+ 391.1322: observed 391.1322.
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(phenyl)methanone (30).
Recrystallization solvent: ethanol; yield 93.0%; mp 200–201 ˝C. IR (KBr, ν cm´1) 1693.5(C=O), 1594.7
(C-C, aromatic), 1365.8, 1136.0 (SO2). 1H-NMR (CDCl3): δ 1.32 (t, 3H, CH3), 3.48 (q, 2H, CH2), 3.68 (s,
3H, OCH3), 3.88 (s, 3H, OCH3), 5.12 (d, 1H, CH), 5.39 (d, 1H, CH), 6.68–7.92 (7H, Ar-H). 13C-NMR
(CDCl3): 13.20, 4594, 48.83, 56.20, 56.32, 62.85, 102.61, 108.00, 128.82, 128.90, 129.10, 130.00, 134.10,
134.57, 150.75, 152.83, 193.70. HR-MS (nES) m/z calcd [M + H]+ 454.0318: observed 454.0316.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(phenyl)methanone (31).
Recrystallization solvent: ethanol; yield 51.5%; mp 121–124 ˝C. IR (KBr, ν cm´1) 1689.1 (C=O), 1597.3
(C-C, aromatic), 1382.9, 1142.8 (SO2). 1H-NMR (CDCl3): δ 3.77 (s, 3H, OCH3), 4.02 (s, 3H, OCH3),
5.759(d, 1H, CH), 7.04 (d, 1H, CH), 7.10–8.12 (m, 12H, Ar-H). 13C-NMR (CDCl3): δ 29.07, 43.56, 56.46,
56.90, 11.25, 112.45, 121.40, 122.28, 125.30, 129.00, 129.03, 129.24, 130.10, 130.70, 134.20, 136.10, 148.20,
152.25, 190.30. HR-MS (nES) m/z calcd [M + H]+ 502.0318: observed 502.0309.
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(phenyl)methanone (32).
Recrystallization solvent: ethanol; yield 91.8%; mp 133–134 ˝C. IR (KBr, ν cm´1) 1685.7 (C=O), 1589.7
(C-C, aromatic), 1359.9, 1145.8 (SO2). 1H-NMR (CDCl3): 3.90 (s, 3H, OCH3), 3.96 (s, 3H, OCH3),
4.38 (d, 1H, CH2), 4.63 (d, 1H, CH2), 5.00 (d, 1H, CH), 5.37 (d, 1H, CH), 7.11–7.85 (12H, Ar-H).
13C-NMR (CDCl3): δ 29.69, 48.50, 52.00, 56.38, 60.50, 98.50, 101.50, 109.00, 122.00, 123.50, 124.00, 128.12,
128.13, 128.68, 128.90. 129.00, 134.00, 135.00, 136.5, 194.00.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-tolyl)methanone (33).
Recrystallization solvent: ethanol; yield 50.6%; mp 176–177 ˝C. IR (KBr, ν cm´1) 1681.6 (C=O), 1505.9
(C-C, aromatic), 1329.3, 1153.8 (SO2). 1H-NMR (CDCl3): δ 2.41 (s, 3H, CH3), 3.85 (d, 1H, CH), 3.92 (s,
3H, OCH3), 3.95 (s, 3H, OCH3), 4.50 (d, 1H, CH), 7.00–8.99 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 21.84,
29.68, 45.94, 55.50, 56.48, 104.18, 106.64, 125.00, 129.05, 129.21, 129.73, 146.00, 151.00, 154.00, 189.60.
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(6,7-Dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-tolyl)
methanone (34). Recrystallization solvent: ethanol; yield 79.7%; mp 183–184 ˝C. IR (KBr, ν cm´1) 1698.9
(C=O), 1575.0 (C-C, aromatic), 1383.0, 1161.1 (SO2). 1H-NMR (CDCl3): δ 2.34 (s, 3H, CH3), 2.59 (s, 3H,
CH3), 2.80 (d, 3H, CH3), 3.93 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.62 (d, 1H, CH), 6.81 (d, 1H, CH),
7.16–7.70 (m, 6H, Ar-H), 11.30, (broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR (CDCl3):
δ 21.41, 29.16, 30.89, 31.66, 56.46, 56.47, 111.86, 112.71, 126.86, 129.00, 129.05, 137.50, 142.00, 148.10,
152.00, 165.00, 188.10. HR-MS (nES) m/z calcd [M + H]+ 405.1479: observed 405.1474.
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-tolyl)methanone (35).
Recrystallization solvent: ethanol; yield 86.0%; mp 157–158 ˝C. IR (KBr, ν cm´1) 1670.8 (C=O), 1605.5
(C-C, aromatic), 1303.6, 1150.4 (SO2). 1H-NMR (CDCl3): δ 1.03 (t, 3H, CH3), 2.41 (s, 3H, CH3), 3.34
(q, 2H, CH2), 3.94 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.05 (d, 1H, CH), 5.37 (d, 1H, CH), 7.17–7.91
(6H, Ar-H). 13C-NMR (CDCl3): δ 12.77, 21.77, 29.68, 45.30, 47.56, 56.39, 61.73, 102.27, 109.15, 129.19,
129.20, 129.74, 130.05, 132.00, 146.00, 151.80, 153.00, 192.80. HR-MS (nES) m/z calcd [M + H]+ 468.0475:
observed 468.0472.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-tolyl)methanone (36).
Recrystallization solvent: ethanol; yield 93.6%; mp 146–147 ˝C. IR (KBr, ν cm´1) 1670.1 (C=O), 1598.9
(C-C, aromatic), 1382.6, 1138.5 (SO2). 1H-NMR (CDCl3): δ 2.4 (s, 3H, CH3), 3.71 (d, 1H, CH), 3.75 (s,
3H, OCH3), 4.00 (s, 3H, OCH3), 5.75 (d, 1H, CH), 7.09–8.01 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.68,
44.00, 46.00, 56.49, 56.50, 112.00, 114.00, 122.13, 125.45, 129.14, 129.20, 129.21, 129.73, 134.05, 145.40,
148.05, 152.34, 190.10. HR-MS (nES) m/z calcd [M + H]+ 516.0475: observed 516.0469.
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-tolyl)methanone (37).
Recrystallization solvent: ethanol; yield 94.8%; mp 151–152 ˝C. IR (KBr, ν cm´1) 1680.3 (C=O), 1606.9
(C-C, aromatic), 1315.7, 1149.1 (SO2). 1H-NMR (CDCl3): δ 2.36 (s, 3H, CH3), 3.89 (s, 3H, OCH3), 3.96 (s,
3H, OCH3), 4.36 (d, 1H, CH2), 4.62 (d, 1H, CH2), 4.98 (d, 1H), 5.35 (d, 1H), 7.12–7.75 (m, 11H, Ar-H).
13C-NMR (CDCl3): δ 21.77, 29.69, 48.07, 51.18, 56.32, 56.37, 102.24, 108.91, 127.85, 128.67, 128.92, 128.96,
129.12, 129.20, 130.10, 132.00, 135.07, 146.05, 151.10, 153.20, 192.45. HR-MS (nES) m/z calcd [M + H]+
530.0631: observed 530.0626.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-chlorophenyl)methanone (38).
Recrystallization solvent: ethanol; yield 73.1%; mp 184–185 ˝C. IR (KBr, ν cm´1) 1686.0 (C=O), 1589.0
(C-C, aromatic), 1334.4, 1152.3 (SO2). 1H-NMR (CDCl3): δ 3.80 (s, 1H, CH), 3.93 (s, 3H, OCH3), 3.95 (s,
3H, OCH3), 4.50 (d, 1H, CH), 7.00–8.06 (m, 6 H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 45.85, 55.43, 56.51,
104.19, 106.64, 124.00, 128.00, 129.46, 130.49, 133.00, 141.00, 151.00, 154.00, 182.00. HR-MS (nES) m/z
calcd [M ´ Br]+ 380.0354: observed 380.0356.
(4-Chlorophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)
methanone (39). Recrystallization solvent: ethanol; yield 83.3%; mp 252–253 ˝C. IR (KBr, ν cm´1) 1668.1
(C=O), 1541.2 (C-C, aromatic), 1381.2, 1144.7 (SO2). 1H-NMR (CDCl3): δ 2.60 (s, 3H, CH3), 2.81 (d, 3H,
NHCH3), 3.93 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 4.85 (broad singlet, 1H, NH (exchangeable with
D2O), 5.57 (d, 1H, CH), 6.78 (d, 1H, CH), 7.24–7.71 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 29.60, 29.69,
32.00, 56.47, 56.49, 91.00, 111.06, 112.25, 127.00, 128.21, 128.57, 137.35, 138.56, 149.34, 152.00, 163.00,
186.25. HR-MS (nES) m/z calcd [M + H]+ 425.0932: observed 425.0931.
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-chlorophenyl)methanone
(40). Recrystallization solvent: ethanol; yield 64.3%; mp 185–186 ˝C. IR (KBr, ν cm´1) 1681.8 (C=O),
1589.9 (C-C, aromatic), 1364.5, 1136.0 (SO2). 1H-NMR (CDCl3): δ 1.26 (t, 3H, CH3), 3.58 (q, 2H, CH2),
3.58 (d, 1H, CH), 3.82 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 5.13 (d, 1H, CH), 6.78–7.90 (m, 6H, Ar-H).
13C-NMR (CDCl3): δ 13.48, 29.69, 39.54, 44.29, 56.28, 56.49, 102.47, 105.91, 127.00, 129.24, 129.67, 131.85,
134.25, 140.05, 150.00, 153.75, 197.00.
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(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-chlorophenyl)methanone
(41). Recrystallization solvent: ethanol; Yield 76.8%; mp 162–164 ˝C. IR (KBr, ν cm´1) 1689.4 (C=O),
1590.1 (C-C, aromatic), 1343.2, 1146.4 (SO2). 1H-NMR (CDCl3): δ 3.76 (s, 3H, OCH3), 4.01 (s, 3H,
OCH3), 5.70 (d, 1H, CH), 7.10 (d, 1H, CH), 7.24–8.06 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 43.70,
46.25, 56.02, 56.20, 112.20, 113.00, 122.00, 126.05, 129.20, 129.27, 129.42, 130.41, 136.00, 141.25, 149.10,
153.70, 189.50. HR-MS (nES) m/z calcd [M + H]+ 535.9929: observed 535.9926.
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-chlorophenyl)methanone
(42). Recrystallization solvent: ethanol; yield 58.1%; mp 166–168 ˝C. IR (KBr, ν cm´1) 1682.5 (C=O),
1589.0 (C-C, aromatic), 1357.9, 1146.9 (SO2). 1H-NMR (CDCl3): δ 3.92 (s, 3H, OCH3), 3.95 (s, 3H,
OCH3), 4.35 (d, H, CH2), 4.57 (d, 1H, CH2), 4.92 (d, 1H), 5.48 (d, 1H), 7.10–7.77 (m, 11H, Ar-H).
13C-NMR (CDCl3): 47.71, 51.71, 56.32, 56.37, 60.90, 102.28, 108.85, 128.12, 128.66, 128.90, 129.67, 129.40,
130.33, 131.25, 132.80, 135.20, 141.20, 150.72, 152.29. 191.73. HR-MS (nES) m/z calcd [M + H]+ 550.0085:
observed 550.0082.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-bromophenyl)methanone (43).
Recrystallization solvent: ethanol; yield 69.8%; mp 193–194 ˝C. IR (KBr, ν cm´1) 1686.0 (C=O), 1585.1
(C-C, aromatic), 1333.8, 1152.1 (SO2). 1H-NMR (CDCl3): δ 3.79 (d, 1H, CH), 3.93 (s, 3H, OCH3), 3.95 (s,
3H, OCH3), 4.50 (d, 1H, CH), 7.00–7.97 (m, 6 H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 45.00, 54.50, 56.51,
106.00, 106.05, 124.00, 127.00, 130.52, 130.60, 132.46, 133.00, 133.05, 154.00, 195.00. HR-MS (nES) m/z
calcd [M ´ Br]+ 423.9849: observed 423.9850.
(4-Bromo-6,7-dimethoxy-2-methyl-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-bromophenyl)methanone
(44). Recrystallization solvent: ethanol; yield 78.8%; mp 189–190 ˝C. IR (KBr, ν cm´1) 1677.3 (C=O),
1585.3 (C-C, aromatic), 1302.6, 1150.3 (SO2). 1H-NMR (CDCl3): δ 2.85 (s, 3H, CH3), 3.94 (s, 3H, OCH3),
3.96 (s, 3H, OCH3), 4.88 (d, 1H, CH), 5.31 (d, 1H, CH), 7.24–7.86 (m, 6 H, Ar-H). 13C-NMR (CDCl3):
δ 29.69, 37.38, 46.81, 56.45, 56.56, 102.66, 109.42128.50, 129.00, 129.50, 130.47, 132.29, 133.10, 151.70,
152.00, 192.00.
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-bromophenyl)methanone
(45). Recrystallization solvent: ethanol; yield 86.3%; mp 171–172 ˝C. IR (KBr, ν cm´1) 1676.6 (C=O),
1583.7 (C-C, aromatic), 1306.2, 1149.4 (SO2). 1H-NMR (CDCl3): δ 1.02 (t, 3H, CH3), 3.33 (q, 2H, CH2),
3.95 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.02 (d, 1H, CH), 5.32 (d, 1H, CH), 7.11–7.87 (m, 6H, Ar-H).
13C-NMR (CDCl3): δ 29.69, 45.20, 47.75, 56.90, 57.00, 62.00, 102.10, 108.80, 110.50, 112.30, 130.20,
130.45, 132.40, 132.60, 151.80, 151.80, 152.10, 192.00. HR-MS (nES) m/z calcd [M + H]+ 517.9267:
observed 517.9264.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-bromophenyl)methanone
(46). Recrystallization solvent: ethanol; yield 89.5%; mp 218–219 ˝C. IR (KBr, ν cm´1) 1688.7 (C=O),
1585.0 (C-C, aromatic), 1382.3, 1145.6 (SO2). 1H-NMR (CDCl3): δ 3.76 (s, 3H, OCH3), 4.01 (s, 3H,
OCH3), 5.70 (d, 1H, CH), 7.05 (d, 1H, CH), 7.11–7.98 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 43.45,
56.05, 56.40, 11.30, 112.10, 120.30, 120.45, 125.37, 127.35, 128.10, 128.45, 129.30, 130.10, 132.10, 132.89,
148.37, 152.35, 189.75. HR-MS (nES) m/z calcd [M + H]+ 579.9423: observed 579.9416.
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-bromophenyl)methanone
(47). Recrystallization solvent: ethanol; yield 80.6%; mp 176–177 ˝C. IR (KBr, ν cm´1) 1685.5 (C=O),
1585.3 (C-C, aromatic), 1293.6, 1146.6 (SO2). 1H-NMR (CDCl3): δ 3.89 (s, 3H, OCH3), 3.96 (s, 3H,
OCH3), 4.33 (d, 1H, CH2), 4.58 (d, 1H, CH2), 4.91 (d, 1H, CH), 5.28 (d, 1H, CH), 7.09–7.70 (m, 11H,
Ar-H). 13C-NMR (CDCl3): δ 29.95, 47.75, 51.45, 56.00, 60.24, 102.00, 108.50, 128.20, 128.69, 128.94,
128.98, 130.39, 132.31, 132.70, 135.10, 135.20, 136.50, 150.50, 152.34, 192.00. HR-MS (nES) m/z calcd
[M + H]+ 593.9580: observed 593.9579.
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(6,7-Dimethoxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-3-yl)(4-fluorophenyl)methanone (48). Recrystallization
solvent: ethanol; yield 58.0%; mp 249–250 ˝C. IR (KBr, ν cm´1) 1638.2 (C=O), 1597.3 (C-C, aromatic),
1363.4, 1152.7 (SO2). 1H-NMR (CDCl3): δ 3.93 (s, 3H, OCH3), 4.01 (s, 3H, OCH3), 6.86–7.84 (m,
7H, Ar-H), 8.2 (broad singlet, 1H, NH (exchangeable with D2O). HR-MS (nES) m/z calcd [M + H]+
534.0381: observed 534.0376.
(4-Bromo-6,7-dimethoxy-2-methyl-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-fluorophenyl)methanone
(49). Recrystallization solvent: ethanol; yield 85.7%; mp 195–196 ˝C. IR (KBr, ν cm´1) 1685.3 (C=O),
1598.0 (C-C, aromatic), 1325.1, 1146.5 (SO2). 1H-NMR (CDCl3): δ 2.10 (s, 3H, CH3), 3.90 (s, 3H, OCH3),
3.91 (s, 3H, OCH3), 4.84 (d, 1H, CH), 5.30 (d, 1H, CH), 7.10–8.00 (m, 6H, Ar-H). 13C-NMR (CDCl3):
δ 29.70, 37.25, 46.25, 56.44, 56.50, 103.56, 110.65, 116.15, 117.50, 128.00, 129.67, 131.45, 132.00, 150.50,
152.00, 192.00. HR-MS (nES) m/z calcd [M + H]+ 458.0068: observed 458.0063.
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-fluorophenyl)methanone
(50). Recrystallization solvent: ethanol; yield 95.3%; mp 190–191 ˝C. IR (KBr, ν cm´1) 1693.4 (C=O),
1598.3 (C-C, aromatic), 1345.8, 1185.0 (SO2). 1H-NMR (CDCl3): δ 3.92 (s, 3H, OCH3), 3.97 (s, 3H,
OCH3), 5.50 (d, 1H, CH), 6.50 (d, 1H, CH), 6.85–8.10 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 16.00, 25.00,
29.70, 38.00, 43.50, 57.00, 110.05, 111.00, 117.00, 117.03, 117.05, 124.00, 131.76, 131.790, 132.00, 164.00,
192.00. HR-MS (nES) m/z calcd [M + H]+ 472.0224: observed 472.0212.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-fluorophenyl)methanone
(51). Recrystallization solvent: ethanol; yield 85.2%; mp 170–171 ˝C. IR (KBr, ν cm´1) 1688.9 (C=O),
1598.8 (C-C, aromatic), 1382.7, 1146.8 (SO2). 1H-NMR (CDCl3): δ 3.76 (s, 3H, OCH3), 3.94 (s, 3H,
OCH3), 5.71 (d, 1H, CH), 7.12 (d, 1H, CH), 7.24–8.16 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.45, 43.75,
56.34, 56.78, 11.10, 112.25, 116.10, 122.00, 122.30, 125.95, 129.30, 129.46, 130.00, 130.80, 131.30, 131.57,
132.00, 152.40, 189.75. HR-MS (nES) m/z calcd [M + H]+ 520.0224: observed 520.0218.
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-fluorophenyl)methanone
(52). Recrystallization solvent: ethanol; yield 87.7%; mp 173–174 ˝C. IR (KBr, ν cm´1) 1683.6 (C=O),
1596.9 (C-C, aromatic), 1356.5, 1147.3 (SO2). 1H-NMR (CDCl3): δ 3.90 (s, 3H, OCH3), 3.96 (s, 3H,
OCH3), 4.38 (d, 1H, CH2), 4.60 (d, 1H, CH2), 4.98 (d, 1H, CH), 5.31 (d, 1H, CH), 7.10–7.89 (m, 11H,
Ar-H). 13C-NMR (CDCl3): δ 29.95, 47.96, 51.87, 56.21, 56.35, 102.35, 109.00, 116.20, 116.25, 128.00,
128.67, 128.94, 130.05, 131.00, 131.50, 132.00, 135.10, 151.58, 152.00, 192.00. HR-MS (nES) m/z calcd
[M + H]+ 534.0381: observed 534.0376.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-chlorophenyl)methanone
(53). Recrystallization solvent: ethanol; yield 53.5%; mp 181–182 ˝C. IR (KBr, ν cm´1) 1686.0 (C=O),
1594.0 (C-C, aromatic), 1328.8, 1149.9 (SO2). 1H-NMR (CDCl3): δ 3.81 (d, 1H, CH), 3.94 (s, 3H, OCH3),
3.96 (s, 3H, OCH3), 4.50 (d, 1H, CH), 7.01–8.04 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 45.95, 55.22, 56.51,
56.85, 104.19, 106.65, 127.33, 128.33, 128.84, 129.50, 130.41, 134.51, 135.49, 136.40, 151.44, 154.07, 188.26.
(3-Chlorophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)
methanone (54). Recrystallization solvent: ethanol; yield 77.0%; mp 176–177 ˝C. IR (KBr, ν cm´1) 1600.9
(C=O), 1505.3 (C-C, aromatic), 1381.1, 1136.4 (SO2). 1H-NMR (CDCl3): δ 2.63 (s, 3H,=3), 2.82 (s, 3H,
CH3), 3.93 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 5.11 (d, 1H, CH), 5.55 (s, 1H, CH), 6.77–7.66 (m, 6H,
Ar-H), 11.28, (broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR (CDCl3): δ 29.06, 30.25, 31.84,
56.48, 56.48, 90.98, 111.71, 112.81, 124.82, 126.97, 126.97, 129.57, 130.79, 135.25, 142.00, 149.40, 153.45,
166.00, 186.00. HR-MS (nES) m/z calcd [M + H]+ 425.0932: observed 425.0927.
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-chlorophenyl)methanone
(55). Recrystallization solvent: ethanol; yield 67.8%; mp 141–142 ˝C. IR (KBr, ν cm´1) 1688.6 (C=O),
1590.7 (C-C, aromatic), 1300.1, 1143.6 (SO2). 1H-NMR (CDCl3): δ 1.04 (t, 3H, CH3), 3.35 (q, 2H, CH2),
3.94 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.02 (d, 1H, CH), 5.32 (d, 1H, CH), 7.18–7.98 (m, 6H, Ar-H).
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13C-NMR (CDCl3): δ 12.65, 45.75, 47, 38, 56.43, 56.75, 61.71, 102.37, 109.07, 127.06, 129.03, 129.91,
130.33, 131.50, 132.50, 134.20, 134.70, 150.87, 152.34, 191.82. HR-MS (nES) m/z calcd [M + H]+ 487.9929:
observed 487.9923.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-chlorophenyl)methanone
(56). Recrystallization solvent: ethanol; yield 78.9%; mp 229–230 ˝C. IR (KBr, ν cm´1) 1701.3 (C=O),
1595.8 (C-C, aromatic), 1337.2, 1140.8 (SO2). 1H-NMR (CDCl3): δ 3.84 (s, 3H, OCH3), 3.96 (s, 3H,
OCH3), 5.40 (d, 1H, CH), 5.80 (d, 1H, CH), 6.90–7.42 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 47.90, 56.37,
56.90, 63.54, 102.97, 107.62, 125.74, 126.78, 128.74, 128.90, 129.78, 130.28, 131.50, 132.00, 134.10, 134.20,
136.50, 138.00, 151.20, 153.12. HR-MS (nES) m/z calcd [M + H]+ 535.9929: observed 535.9925.
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-chlorophenyl)methanone
(57). Recrystallization solvent: ethanol; yield 74.4%; mp 154–155 ˝C. IR (KBr, ν cm´1) 1691.2 (C=O),
1591.8 (C-C, aromatic), 1335.9, 1138.2 (SO2). 1H-NMR (CDCl3): δ 3.90 (s, 3H, OCH3), 3.96 (s, 3H,
OCH3), 4.40 (d, 1H, CH2), 4.57 (d, 1H, CH2), 4.97 (d, 1H, CH), 5.27 (d, 1H, CH), 7.10–7.85 (m, 11H,
Ar-H). 13C-NMR (CDCl3): δ 47.75, 51.78, 56.35, 56.39, 60.95, 102.31, 108.85, 126.50, 127.69, 128.22,
128.70, 128.93, 130.19, 131.50, 134.17, 134.50, 134.70, 135.30, 135.50, 151.50, 152.10, 192.00. HR-MS (nES)
m/z calcd [M + NH4]+ 567.0351: observed 567.0345.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-bromophenyl)methanone
(58). Recrystallization solvent: ethanol; yield 44.5%; mp 177–178 ˝C. IR (KBr, ν cm´1) 1685.9 (C=O),
1587.6 (C-C, aromatic), 1328.8, 1149.3 (SO2). 1H-NMR (CDCl3): δ 3.80 (d, 1H, CH), 3.93 (s, 3H, OCH3),
3.95 (s, 3H, OCH3), 4.49 (d, 1H, CH), 7.00–8.19 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 29.95, 46.10, 55.10,
56.51, 104.10, 106.80, 123.50, 126.40, 127.50, 128.10, 131.35, 131.86, 136.40, 137.24, 151.75, 153.95, 188.10.
HR-MS (nES) m/z calcd [M + HBr]+ 423.9849: observed 423.9850.
(3-Bromophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)
methanone (59). Recrystallization solvent: ethanol; yield 76.4%; mp 178–179 ˝C. IR (KBr, ν cm´1) 1678.8
(C=O), 1570.4 (C-C, aromatic), 1311.2, 1136.4 (SO2). 1H-NMR (CDCl3): δ 2.63 (s, 3H, CH3), 2.82 (d, 3H,
NHCH3), 3.93 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 5.55 (d, 1H, CH), 6.77 (d, 1H, CH), 7.21–7.84 (m, 6H,
Ar-H), 11.31 (broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR (CDCl3): δ 29.68, 29.80, 31.83,
56.49, 56.90, 91.20, 111.69, 112.20, 123.10, 125.32, 126.23, 128.10, 129.93, 133.74, 141.35, 149.45, 152.00,
159.56, 186.34. HR-MS (nES) m/z calcd [M + H]+ 469.0427: observed 469.0419.
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-bromophenyl)methanone
(60). Recrystallization solvent: ethanol; yield 85.2%; mp 130–131 ˝C. IR (KBr, ν cm´1) 1689.3 (C=O),
1590.2 (C-C, aromatic), 1350.4, 1142.9 (SO2). 1H-NMR (CDCl3): δ 1.02 (t, 3H, CH3), 3.36 (q, 2H, CH2),
3.94 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.03 (d, 1H, CH), 5.32 (d, 1H, CH), 7.17–8.14 (m, 6H, Ar-H).
13C-NMR (CDCl3): δ 12.64, 29.69, 45.74, 47.35, 56.43, 61.70, 101.70, 108.00, 122.10, 126.20, 128.20, 130.05,
131.15, 136.05, 137.25, 138.15, 150.25, 152.15, 192.15. HR-MS (nES) m/z calcd [M + H]+ 531.9423:
observed 531.9421.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-bromophenyl)methanone
(61). Recrystallization solvent: ethanol; yield 80.2%; mp 232–233 ˝C. IR (KBr, ν cm´1) 1701.6 (C=O),
1595.3 (C-C, aromatic), 1284.2, 1141.5 (SO2). 1H-NMR (CDCl3): δ 3.85 (s, 3H, OCH3), 3.91 (s, 3H,
OCH3), 5.45 (d, 1H, CH), 5.80 (d, 1H, CH), 6.80–7.94 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 51.93, 56.24,
56.38, 56.48, 62.06, 102.53, 108.04, 127.33, 127.43, 128.17, 129.18, 129.40, 130.03, 132.67, 133.84, 134.86,
138.10, 150.96, 152.97, 196.11. HR-MS (nES) m/z calcd [M + NH4]+ 596.9689: observed 596.9685.
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-bromophenyl)methanone
(62). Recrystallization solvent: ethanol; Yield 96.9%; mp 167–168 ˝C. IR (KBr, ν cm´1) 1690.8 (C=O),
1590.8 (C-C, aromatic), 1334.6, 1137.9 (SO2). 1H-NMR (CDCl3): δ 3.90 (s, 3H, OCH3), 3.91 (s, 3H,
OCH3), 4.40 (d, 1H, CH2), 4.56 (d, 1H, CH2), 4.97 (d, 1H, CH), 5.26 (d, 1H, CH), 7.10–7.96 (m, 11H,
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Ar-H). 13C-NMR (CDCl3): δ 29.69, 47.72, 56.35, 56.39, 60.97, 102.31, 108.85, 122.80, 127.40, 127.75,
128.24, 128.60, 128.71, 128.93, 130.41, 131.89, 135.10, 136.20, 137.25, 151.45, 152.10, 192.23. HR-MS (nES)
m/z calcd [M + NH4]+ 610.9845: observed 610.9842.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-chlorophenyl)methanone
(63). Recrystallization solvent: ethanol; yield 72.8%; mp 185–186 ˝C. IR (KBr, ν cm´1) 1696.5 (C=O),
1677.0 (C-C, aromatic), 1337.3, 1153.7 (SO2). 1H-NMR (CDCl3): δ 3.80 (d, 1H, CH), 3.91 (s, 3H, OCH3),
3.95 (s, 3H, OCH3), 4.41 (d, 1H, CH), 6.97–7.53 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 47.50, 56.49,
56.51, 104.00, 106.00, 122.00, 125.00, 126.50, 130.79, 133.90, 147.50, 153.50, 160.0, 161.90, 192.00.
(2-Chlorophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4dihydro-2H-benzo[e][1,2]thiazin-3-yl)
methanone (64). Recrystallization solvent: ethanol; yield 65.4%; mp 118–119 ˝C. IR (KBr, ν cm´1) 1602.0
(C=O), 1568.8 (C-C, aromatic), 1309.7, 1147.6 (SO2). 1H-NMR (CDCl3): δ 2.56 (s, 3H, CH3), 2.81 (s, 3H,
CH3), 3.92 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 4.91 (d, 1H, CH), 5.26 (s, 1H, CH), 7.24–7.52 (m, 6H,
Ar-H), 6.76, (broad singlet, 1H, NH. 13C-NMR (CDCl3): δ 27.80, 32.00, 56.50, 57.50, 95.00, 101.00, 101.90,
111.00, 112.00, 126.00, 127.00, 129.92, 130.00, 131.00, 132.00, 164.00, 190.00. HR-MS (nES) m/z calcd
[M + H]+ 425.0932: observed 425.0928.
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-chlorophenyl)methanone
(65). Recrystallization solvent: ethanol; yield 48.2%; mp 129–131 ˝C. IR (KBr, ν cm´1) 1701.3 (C=O),
1589.9 (C-C, aromatic), 1383.4, 1141.1 (SO2). 1H-NMR (CDCl3): δ 1.31 (t, 3H, CH3), 3.44 (q, 2H, CH2),
3.82 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 5.29 (d, 1H, CH), 5.44 (d, 1H, CH), 6.86–7.74 (m, 6H, Ar-H).
13C-NMR (CDCl3): δ 45.04, 51.63, 52.98, 56.01, 61.49, 62.44, 102.36, 10258, 108.08, 108.72, 127.04, 127.09,
127.68, 130.93, 132.95, 150.85, 152.44, 152.92, 193.34. HR-MS (nES) m/z calcd [M + H]+ 487.9927:
observed 487.9918.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-chlorophenyl)methanone
(66). Recrystallization solvent: ethanol; yield 84.2%; mp 209–210 ˝C. IR (KBr, ν cm´1) 1710.0 (C=O),
1587.7 (C-C, aromatic), 1304.6, 1144.7 (SO2). 1H-NMR (CDCl3): δ 3.96 (s, 3H, OCH3), 3.98 (s, 3H,
OCH3), 5.52 (d, 1H, CH), 5.80 (d, 1H, CH), 6.80–7.94 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 52.05,
56.42, 56.46, 102.45, 108.20, 126.36, 126.78, 127.14, 127.56, 127.85, 128.45, 129.56, 130.04, 132.05, 133.56,
137.34, 136.00, 150.78, 153.45, 196.67. HR-MS (nES) m/z calcd [M + H]+ 535.9929 535: observed 535.9924.
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-chlorophenyl)methanone
(67). Recrystallization solvent: ethanol; yield 90.8%; mp 156–157 ˝C. IR (KBr, ν cm´1) 1692.5 (C=O),
1592.0 (C-C, aromatic), 1342.2, 1140.2 (SO2). 1H-NMR (CDCl3): δ 3.89 (s, 3H, OCH3), 3.95 (s, 3H,
OCH3), 4.45 (d, 1H, CH2), 4.70 (d, 1H, CH2), 5.05 (d, 1H, CH), 5.28 (d, 1H, CH), 7.01–7.42 (m, 11H,
Ar-H). 13C-NMR (CDCl3): δ 29.70, 50.75, 52.52, 56.38, 60.45, 102.34, 108.25, 126.50, 127.34, 128.50,
128.78, 129.04, 129.42, 130.87, 131.50, 132.23, 135.60, 135.80, 136.00, 150.70, 152.10, 194.00. HR-MS (nES)
m/z calcd [M + NH4]+ 567.0351: observed 567.0342.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-bromophenyl)methanone
(68). Recrystallization solvent: ethanol; yield 56.6%; mp 183–184 ˝C. IR (KBr, ν cm´1) 1696.7 (C=O),
1676.3 (C-C, aromatic), 1336.3, 1153.2 (SO2). 1H-NMR (CDCl3): δ 3.85 (s, 3H, OCH3), 3.91 (s, 3H,
OCH3), 5.45 (d, 1H, CH), 5.78 (d, 1H, CH) 6.98–7.93 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 47.96,
56.41, 63.53, 102.97, 107.62, 124.10, 125.74, 127.21, 128.00, 129.79, 130.50, 131.65, 137.26. 138.05, 150.12,
190.45. HR-MS (nES) m/z calcd [M ´ Br]+ 423.9849: observed 423.9849.
(2-Bromophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)
methanone (69). Recrystallization solvent: ethanol; yield 75.2%; mp 122–123 ˝C. IR (KBr, ν cm´1) 1737.9
(C=O), 1655.7 (C-C, aromatic), 1383.0, 1147.1 (SO2). 1H-NMR (CDCl3): δ 2.55 (s, 3H, CH3), 2.83 (s, 3H,
CH3), 3.93 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 4.80 (d, 1H, CH), 5.16 (s, 1H, CH), 6.77–7.53 (m, 6H,
Ar-H), 11.35, (broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR (CDCl3): δ 29.31, 29.78, 31.82,
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56.51, 56.58, 94.73, 11.70, 112.76, 118.00, 127.44, 128.79, 129.40, 130.21, 130.75, 133.01, 143.45, 148.12,
151.75, 164.91, 192.30. HR-MS (nES) m/z calcd [M + H]+ 469.0427: observed 469.0418.
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-bromophenyl)methanone
(70). Recrystallization solvent: ethanol; yield 69.3%; mp 129–130 ˝C. IR (KBr, ν cm´1) 1689.5 (C=O),
1590.1 (C-C, aromatic), 1350.4, 1142.8 (SO2). 1H-NMR (CDCl3): δ 1.05 (t, 3H, CH3), 3.35 (q, 2H, CH2),
3.89 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 5.03 (d, 1H, CH), 5.29 (d, 1H, CH), 7.19–8.15 (m, 6H, Ar-H).
13C-NMR (CDCl3): 12.64, 45.73, 47.34, 56.35, 56.41, 61.69, 102.35, 109.05, 123.37, 127.48, 129.89, 130.53,
131.94, 132.20, 136.00, 137.08, 150.85, 152.32, 191.72.
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-bromophenyl)methanone
(71). Recrystallization solvent: ethanol; yield 96.8%; mp 210–211 ˝C. IR (KBr, ν cm´1) 1709.5 (C=O),
1588.1 (C-C, aromatic), 1305.1, 1144.7 (SO2). 1H-NMR (CDCl3): δ 3.96 (s, 3H, OCH3), 3.98 (s, 3H,
OCH3), 5.52 (d, 1H, CH), 5.79 (d, 1H, CH), 7.24–7.62 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.69, 51.96,
56.42, 56.51, 102.45, 108.23, 119.50, 126.60, 126.85, 127.25, 127.45, 128.85, 128.95, 130.06, 132.32, 132.85,
134.23, 138.45, 151.50, 151.80, 196.10. HR-MS (nES) m/z calcd [M + H]+ 579.9423: observed 579.9423.
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-bromophenyl)methanone
(72). Recrystallization solvent: ethanol; yield 81.6%; mp 123–125 ˝C. IR (KBr, ν cm´1) 1690.6 (C=O),
1590.4 (C-C, aromatic), 1334.3, 1137.9 (SO2). 1H-NMR (CDCl3): δ 3.89 (s, 3H, OCH3), 3.96 (s, 3H,
OCH3), 4.39 (d, 1H, CH2), 4.55 (d, 1H, CH2), 4.97 (d, 1H, CH), 5.27 (d, 1H, CH), 7.10–7.96 (m, 11H,
Ar-H). 13C-NMR (CDCl3): 47.72, 51.74, 56.34, 56.38, 60.97, 102.30, 108.83, 123.80, 127.37, 128.21, 128.68,
128.89, 130.40, 131.85, 135.00, 135.60, 140.10, 150.74, 152.32, 191.62. HR-MS (nES) m/z calcd [M + H]+
593.9580: observed 593.9578.
4.6. Antimicrobial Activity
For determining the antibacterial activities, the synthesized compounds were dissolved in
DMSO (20 mg/mL). Broth dilution method in a 96 wells micro-titre plate was used to test the
compounds (27–72) [6]. Mueller Hinton Broth was used as diluents in the wells of the micro-titre plate.
The dilutions were prepared at the required quantities of 600, 500, 400, 200, 100, 50, 25, 12.5 µg/mL.
Equal volume of bacterial culture was added to it after comparing it with 0.5 McFarland standard and
incubated at 37 ˝C for 16 to 18 h on a rotary shaker at 150 rpm [39]. Plates were then examined for
the turbidity as an indicator of growth and the absorbance was taken with the help of ELISA reader
at 590 nm [40]. First well that appeared having zero absorbance was taken to be the MIC (Minimum
inhibitory concentration) [8]. This was followed by an MTT assay for confirmation. Streptomycin
was used as a reference control at concentrations of 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39 µg/mL.
Streptomycin is a broad spectrum antibiotic which inhibits the growth of both Gram-positive and
Gram-negative bacteria and has been widely used as a reference [41,42]. In order to ensure that the
solvent had no effect on bacterial growth, a control test was also performed containing inoculated
broth supplemented with different concentrations (1%–16%) of DMSO. All the tests were performed
in triplicates.
The MBC (minimum bactericidal concentration) was determined by sub culturing the preparations
that have shown no evidence of growth on Mueller Hinton Agar in neat and dilutions of 1:10 and
1:100. A colony-forming unit (CFU) count was done for the agar plates and the dilution that gave
99.9% reduction to the original inoculum was considered to be the MBC.
All the compounds were tested for their in vitro growth inhibitory activity against different
bacteria. The bacterial strains used were Bacillus subtilis ATCC 6633 and Staphylococcus aureus ATCC
6538 as Gram-positive bacteria and Salmonella typhimurium ATCC 14028 (Salmonella enterica) and
Proteus vulgaris ATCC 13315 as Gram-negative bacteria. Staphylococcus aureus is a clinically important
pathogen as it causes various types of infections [43] and Bacillus subtilis was used as a model organism
as it belongs to the same group as pathogenic Bacillus anthracis species [44]. Salmonella typhimurium
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is clinically important as it can cause enteritis. Proteus vulgaris has been isolated from long term care
facilities and hospitals and from immunocompromised patients. The strains used in this study were
obtained from culture collection of University of Hertfordshire.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/21/
7/861/s1.
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